There has been no news about Jaguar Health Inc (NASDAQ:JAGX) in recent days but the company is in considerable focus among investors and that might be related to a development from back in August.
Back on August 23, the company’s fully owned subsidiary company Napo Pharmaceuticals made a key announcement with regards to a clinical study. At the time, Napo announced that an abstract which is related to an exploratory clinical study with regards to the effect that its product Mytesi might have on gastrointestinal microbe in people suffering from AIDS had been submitted to be considered for presentation at a major event.
The event in question is the IDWeek 2021 and it is going to take place from September 29 to October 3. Mytesi is a product that helps in combating diarrhea in HIV positive patients and the potential presence of the company at a key industry event is something that investors might be following closely.
While there has been no fresh news about Napo in recent days, it is likely that any news with regards to the presence of the company at the event could bring a larger focus on the Jaguar Health stock.
